| Patents for C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof (26,637) |
|---|
| 02/10/2000 | WO2000006717A2 Improved transformation efficiency in phage display through modification of a coat protein |
| 02/10/2000 | WO2000006205A1 Regulated expression of recombinant proteins using rna viruses |
| 02/10/2000 | WO1999045126A3 Enhanced prodrug activation |
| 02/10/2000 | CA2334170A1 Improved transformation efficiency in phage display through modification of a coat protein |
| 02/09/2000 | EP0978566A2 Chimaeric adenoviruses |
| 02/09/2000 | EP0977886A1 Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
| 02/09/2000 | EP0977881A1 Expression of a modified foamy virus envelope protein |
| 02/09/2000 | EP0977879A2 Eukaryotic gene expression cassette and uses thereof |
| 02/09/2000 | EP0977832A1 Method for inactivating a virus |
| 02/09/2000 | EP0977587A1 Chimeric flavivirus vaccines |
| 02/09/2000 | EP0751988B1 Highly efficient production and isolation of viral particles |
| 02/09/2000 | CN1244215A Improved method for the production and purification of adenoviral vectors |
| 02/09/2000 | CN1243878A Process for preparing full-function helper virus used for production of recombinant adeno-associated virus and its usage |
| 02/08/2000 | US6022735 Composition for introducing nucleic acid complexes into higher eucaryotic cells |
| 02/08/2000 | US6022726 Genetically engineered attenuated viruses |
| 02/03/2000 | WO2000005394A1 Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates |
| 02/03/2000 | WO2000005347A2 Hepatitis b culture system |
| 02/03/2000 | WO1999061052A3 Oral immunization with papillomavirus virus-like particles |
| 02/03/2000 | WO1999061049A3 Model for infection by a pathogen using administration of nucleic acids |
| 02/03/2000 | WO1999054349A3 Dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 02/03/2000 | WO1999051263A3 Methods and modified cells for the treatment of cancer |
| 02/02/2000 | EP0975787A1 Entomopoxvirus-based gene delivery vector for vertebrates |
| 02/02/2000 | EP0975214A1 Improved storage and maintenance of blood products |
| 02/01/2000 | US6020182 Subunit respiratory syncytial virus vaccine preparation |
| 02/01/2000 | US6019978 Replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| 02/01/2000 | CA2035039C Recombinant poxvirus and streptococcal m protein vaccine |
| 01/27/2000 | WO1999064604A3 Attenuated pestiviruses |
| 01/27/2000 | WO1999061639A3 Retroviral delivery system |
| 01/27/2000 | WO1999058655A3 Phage display selection system for folded proteins |
| 01/27/2000 | WO1999053959A3 Use of viral vectors for treatment of the injured peripheral and central nervous system |
| 01/26/2000 | EP0974668A1 Use of adenoviral E4 reading frames to improve expression of a gene of interest |
| 01/26/2000 | EP0974660A1 Newcastle disease virus infectious clones, vaccines and diagnostic assays |
| 01/26/2000 | EP0974659A2 Viral nucleotide sequences |
| 01/26/2000 | EP0973927A1 Chimeric adenoviral coat protein and methods of using same |
| 01/26/2000 | EP0973924A1 Recombinant chimeric viruses and uses thereof |
| 01/26/2000 | EP0973916A1 Composition and method for inducing an immune response against tumour-related antigens |
| 01/26/2000 | EP0973879A2 Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products |
| 01/26/2000 | EP0973802A1 Synthetic peptides useful in biological assays for detecting infections caused by group o hiv-1 viruses |
| 01/26/2000 | EP0973546A2 Stabilized human papillomavirus formulations |
| 01/26/2000 | EP0973538A1 Modified proteins which bind extracellular matrix components |
| 01/26/2000 | EP0973381A2 Animal model for evaluation of vaccines |
| 01/25/2000 | US6018027 A polypeptide encoding a nucleic acid having morphology of herpes virus and a double stranded dna genome designated as a new human b lymphotropic virus; diagnosis and therapy |
| 01/25/2000 | US6017761 Isolating nucleic acid sequence encoding a minimal open reading frame and inserting into a plasmid, then transformed into eukaryotic cells that are free of endogenous retroviral nucleic acid, producing recombinant retroviral cells |
| 01/25/2000 | US6017759 Chimeric infectious bursal disease virus cDNA clones, expression products and vaccines based thereon |
| 01/25/2000 | US6017732 To screen for enhanced specfic binding pair binding |
| 01/25/2000 | US6017535 cDNA sequence of Dengue virus serotype 1 (Singapore strain) |
| 01/20/2000 | WO2000003029A2 Chimaeric adenoviruses |
| 01/20/2000 | WO2000002909A2 Amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins |
| 01/20/2000 | WO2000002524A2 Botulinum neurotoxin vaccine |
| 01/20/2000 | WO1999046288A3 A process for isolating and purifying viruses, soluble proteins and peptides from plant sources |
| 01/20/2000 | CA2336587A1 Botulinum neurotoxin vaccine |
| 01/20/2000 | CA2333855A1 Isolated amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins |
| 01/19/2000 | EP0972841A1 Display of viral proteins as ligands for cell-surface receptor |
| 01/19/2000 | EP0972828A1 Process for the in vitro replication of HCV |
| 01/19/2000 | EP0972064A1 Methods for producing retroviral vectors with an altered tropism |
| 01/19/2000 | EP0972063A2 Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
| 01/19/2000 | EP0972047A2 Papilloma virus main capsid protein and the use thereof in diagnosis, therapy and vaccination |
| 01/19/2000 | EP0654086B1 Vaccines against aujeszky's disease and other animal diseases containing pseudorabies virus mutants |
| 01/19/2000 | EP0587873B1 Process for the production of cells infected by a multiple sclerosis associated virus |
| 01/19/2000 | CN1242051A Cytopathic viruses for therapy and prophylaxis of neoplasia |
| 01/19/2000 | CN1242045A Immunotherapy and improved vaccines |
| 01/19/2000 | CN1241901A Coat protein mediated resistance in plants |
| 01/19/2000 | CN1241632A Gene engineering adenovirus and its application |
| 01/18/2000 | US6015695 Immunoglobulins devoid of light chains |
| 01/18/2000 | CA1340875C Variants of lav viruses their dna- and protein- components and their uses, particularly for diagnostic purposes and for the preparation of immunogenic compositions |
| 01/13/2000 | WO2000001835A2 Targeted integration into chromosomes using retroviral vectors |
| 01/13/2000 | WO2000001834A1 Recombinant herpes viruses for preparing recombinant adeno-associated viruses |
| 01/13/2000 | WO2000001409A2 Porcine circovirus and parvovirus vaccine |
| 01/13/2000 | WO1999060148A3 Display of viral proteins as ligands for cell-surface receptor |
| 01/13/2000 | WO1999053047A3 Porcine adenovirus type 3 genome |
| 01/13/2000 | DE19830141A1 Rekombinante Herpesviren für die Erzeugung rekombinanter Adeno-Assoziierter-Viren Recombinant herpes viruses for the production of recombinant adeno-associated virus |
| 01/12/2000 | EP0970220A1 Method for producing non-infectious recombinant picornavirus particles |
| 01/12/2000 | EP0970201A1 Retroviral vectors capable of transducing non-dividing cells |
| 01/12/2000 | EP0970189A1 In vitro model for hiv and other viral diseases |
| 01/12/2000 | EP0969863A1 Viral defective interfering particles and uses thereof |
| 01/12/2000 | EP0969862A2 SYNTHETIC HIV $i(GAG) GENES |
| 01/12/2000 | EP0572401B1 Viral particles having altered host range |
| 01/12/2000 | EP0548234B1 Cloning of chicken anaemia dna |
| 01/12/2000 | CN1241216A Non-mammalian DNA virus having altered coat protein |
| 01/11/2000 | US6013780 VEGF145 expression vectors |
| 01/11/2000 | US6013516 Vector and method of use for nucleic acid delivery to non-dividing cells |
| 01/11/2000 | US6013484 HIV-3 retrovirus and its use |
| 01/11/2000 | US6013265 For immunization against and preventing clinical symptoms associated with herpes simplex virus infections |
| 01/11/2000 | US6013261 For immunization |
| 01/07/2000 | CA2276791A1 Use of adenoviral e4 reading frames to improve expression of a gene of interest |
| 01/06/2000 | WO2000000629A1 High efficiency retroviral vectors that contain none of viral coding sequences |
| 01/06/2000 | WO2000000628A1 Replication-defective recombinant adenovirus with mutated major late promoter |
| 01/06/2000 | WO2000000617A2 Ebola virion proteins expressed from venezuelan equine encephalitis (vee) virus replicons |
| 01/06/2000 | WO2000000616A2 Marburg virus vaccines |
| 01/06/2000 | WO2000000589A1 High-efficiency aav helper functions |
| 01/06/2000 | WO2000000225A1 Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby |
| 01/06/2000 | WO2000000216A2 Use of poxviruses as enhancer of specific immunity |
| 01/06/2000 | CA2336554A1 Marburg virus vaccines |
| 01/06/2000 | CA2335508A1 Use of poxviruses as enhancer of specific immunity |
| 01/06/2000 | CA2332494A1 Ebola virion proteins expressed from venezuelan equine encephalitis (vee) virus replicons |
| 01/06/2000 | CA2332181A1 Replication-defective recombinant adenovirus with mutated major late promoter |
| 01/05/2000 | EP0968724A1 Use of viral vectors for treatment of the injured peripheral and central nervous system |
| 01/05/2000 | EP0968297A1 Live recombinant avian vaccine using the avian infectious laryngotracheitis virus as vector |
| 01/05/2000 | EP0968284A2 An improved method for the production and purification of adenoviral vectors |
| 01/05/2000 | EP0968278A1 Attenuated polioviruses |